CZR three-lens brief
Evidence-based stock research on CZR. Three independent lenses — Quality, Momentum, Context — examine live data from SEC filings, the Federal Reserve, and market feeds. Every claim traces to its primary source.
Underperforming SPY by 8.2pp over 30 days. · Currently unprofitable on a trailing basis — no P/E multiple available.
- Underperforming SPY by 8.2pp over 30 days.
- Currently unprofitable on a trailing basis — no P/E multiple available.
- Analyst mean target $32.83 — 17% above current (18 analysts).
- Debt-to-equity of 695.1 — balance-sheet-heavy.
CZR closed at $28.12 (+0.68%) as of 2026-04-25. Market cap: $5.73B. Positives: analyst mean target $32.83 — 17% above current (18 analysts).. Concerns: underperforming SPY by 8.2pp over 30 days.; currently unprofitable on a trailing basis — no P/E multiple available.. Last quarter: Revenue $2.92B, net income -$250.00M, free cash flow $693.25M.
Why three lenses on CZR, not one.
A single reasoning model has blind spots it doesn’t know about. We examine CZRacross Quality (fundamentals), Momentum (price action and sentiment), and Context (macro/sector). Disagreement between lenses is surfaced, not hidden — it’s how you know when HOLD is the honest call.
Read the full methodologyDrop it in your newsletter or blog.
Free to embed. Updates every 6 hours. Links back to the full brief.
<iframe src="https://clearpathinvest.app/embed/CZR" width="100%" height="420" frameborder="0" loading="lazy" title="ClearPath CZR brief"></iframe>